Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that acts on Akt1 (IC50: 8 nM), Akt2 (IC50: 12 nM) and Akt3 (IC50: 65 nM). Many breast cancer cell lines, PIK3CA mutants and PTEN-losing cell lines are sensitive to MK-2206, which has anti-cancer effects.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 491,500 |
50 mg | 約6-8 週間 | ¥ 639,500 |
100 mg | 約6-8 週間 | ¥ 808,000 |
説明 | MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that acts on Akt1 (IC50: 8 nM), Akt2 (IC50: 12 nM) and Akt3 (IC50: 65 nM). Many breast cancer cell lines, PIK3CA mutants and PTEN-losing cell lines are sensitive to MK-2206, which has anti-cancer effects. |
分子量 | 443.94 |
分子式 | C25H22ClN5O |
CAS No. | 1032349-77-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MK-2206 1032349-77-1 Inhibitor inhibitor inhibit